RIA
TVRD

Realta Investment Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Realta Investment Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-6
Closed -$5K – 1455
2019
Q4 		$5K Hold
6
– – ﹤0.01% 1357
2019
Q3 		$4K Buy
+6
New +$4.99K ﹤0.01% 1408

Other funds holding TVRD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Realta Investment Advisors's TVRD Position: Q1 2020 in Review

Realta Investment Advisors sold out of Tvardi Therapeutics (TVRD) in Q1 2020, closing a stake of 6 shares — an estimated $5K sold.

Realta Investment Advisors first reported a position in TVRD in Q3 2019 and held it in 2 quarters. The position peaked at $5K in Q4 2019. 133 funds tracked by Wall St. Rank hold TVRD as of Q1 2020.

  • Realta Investment Advisors reported no remaining Tvardi Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Realta Investment Advisors sold 6 Tvardi Therapeutics shares in Q1 2020, an estimated $5K.
  • Realta Investment Advisors first reported a position in Tvardi Therapeutics in Q3 2019 and held it in 2 quarters.
  • Realta Investment Advisors's Tvardi Therapeutics position peaked at $5K in Q4 2019.
  • 133 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2020.

Based on Realta Investment Advisors's 13F filing for Q1 2020, filed 23 Apr 2020.